Diagnosis and treatment of pediatric pulmonary arterial hypertension.

Adult; Child; Heart Defects, Congenital/complications; Humans; Hypertension, Pulmonary/physiopathology/therapy; Registries; Paediatric; diagnosis; pulmonary arterial hypertension; treatment

Abstract :

[en] INTRODUCTION: Pediatric pulmonary arterial hypertension (PAH) remains a rare and severe disease with a poor prognosis. PAH may be idiopathic, heritable or associated with systemic conditions in particular associated with congenital heart disease. Areas covered: A thorough and extensive diagnostic approach is required for a correct diagnosis. The outcome has improved over the last decade with a better diagnostic approach and with the initiation of new targeted therapies. However, there is still significant progress to achieve as there is still no cure for this devastating disease. Expert opinion: Adapted clinical studies to define the best therapeutic approach are needed. Even if the treatment approach is still mainly derived from adult data and expert consensus, several studies and registries are currently underway and should deliver important information in the next future. This review aims to give an overview of the current diagnosis and treatment strategies of PAH.

Disciplines :

Pediatrics
Cardiovascular & respiratory systems

Author, co-author :

FARHAT, Nesrine ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie

Lador, Frederic

Beghetti, Maurice

Language :

English

Title :

Diagnosis and treatment of pediatric pulmonary arterial hypertension.

Publication date :

March 2019

Journal title :

Expert Review of Cardiovascular Therapy

ISSN :

1477-9072

eISSN :

1744-8344

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

161-175

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 17 February 2020

Statistics

Number of views

51 (6 by ULiège)

Number of downloads

5 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Frank BS, Ivy DD., Diagnosis, evaluation and treatment of pulmonary arterial hypertension in children. Children (Basel). 2018 Mar 23;5:4.
Hansmann G, Apitz C, Abdul-Khaliq H, et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart. 2016 May;102(Suppl 2):ii86–100.
Koestenberger M, Hansmann G, Apitz C, et al. Diagnostics in children and adolescents with suspected or confirmed pulmonary hypertension. Paediatr Respir Rev [Internet]. 2017 Jun 1 [cited 2018 Jun13];23:3–15. Available from: http://www.sciencedirect.com/science/article/pii/S1526054216301208
Hansmann G., Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol. 2017 May 23;69(20):2551–2569.
Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25Suppl):D117–126.
Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American heart association and American thoracic society. Circulation [Internet]. 2015 Nov 24 [cited 2018 Aug18];132(21):2037–2099. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIR.0000000000000329
Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet [Internet]. 2012 Feb [cited 2018 Oct4];379(9815):537–546. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673611616218
Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol [Internet]. 2013 Dec;62(25):D34–41. [cited 2018 Aug23]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109713058725
Lador F, Sekarski N, Beghetti M. Treating pulmonary hypertension in pediatrics. Expert Opin Pharmacother. 2015 Apr;16(5):711–726.
Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension the joint task force for the diagnosis and treatment of pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J [Internet]. 2016 Jan 1 [cited 2018 Aug26];37(1):67–119. Available from: https://academic.oup.com/eurheartj/article/37/1/67/2887599
Rosenzweig EB, Feinstein JA, Humpl T, et al. Pulmonary arterial hypertension in children: diagnostic work-up and challenges. Prog Pediatr Cardiol [Internet]. 2009 Dec cited 2018 Aug25;27(1):4–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117303/
Beghetti M, Rmf B, Schulze-Neick I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J. 2013 Sep;42(3):689–700.
Levy M, Eyries M, Szezepanski I, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J [Internet]. 2016 Oct 1 [cited 2018 Aug23];48(4):1118–1126. Available from: http://erj.ersjournals.com/content/48/4/1118
Kerstjens-Frederikse WS, Bongers EMHF, Roofthooft MTR, et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet [Internet]. 2013 Aug [cited 2018 Aug23];50(8):500–506. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717587/
Koestenberger M, Avian A, Gamillscheg A, et al. Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: results from the European pediatric pulmonary vascular disease network. Clin Cardiol [Internet]. [cited 2018 Aug23]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/clc.22994
Koestenberger M, Avian A, Sallmon H, et al. The right ventricular outflow tract in pediatric pulmonary hypertension—data from the European pediatric pulmonary vascular disease network. Echocardiography [Internet]. 2018 Jun 1 [cited 2018 Aug23];35(6):841–848. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/echo.13852
Jone P-N, Schäfer M, Pan Z, et al. 3D echocardiographic evaluation of right ventricular function and strain: a prognostic study in paediatric pulmonary hypertension. Eur Heart J Cardiovasc Imaging [Internet]. 2018 Sep 1 [cited 2018 Aug23];19(9):1026–1033. Available from: https://academic.oup.com/ehjcimaging/article/19/9/1026/4093951
Okumura K, Humpl T, Dragulescu A, et al. Longitudinal assessment of right ventricular myocardial strain in relation to transplant-free survival in children with idiopathic pulmonary hypertension. J Am Soc Echocardiography [Internet]. 2014 Dec [cited 2018 Aug24];27(12):1344–1351. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0894731714006610
Muntean I, Benedek T, Melinte M, et al. Deformation pattern and predictive value of right ventricular longitudinal strain in children with pulmonary arterial hypertension. Cardiovasc Ultrasound [Internet]. 2015 Dec [cited 2018 Aug24];14(1). Available from: http://cardiovascularultrasound.biomedcentral.com/articles/10.1186/s12947-016-0074-3
Motoji Y, Tanaka H, Fukuda Y, et al. Efficacy of right ventricular free-wall longitudinal speckle-tracking strain for predicting long-term outcome in patients with pulmonary hypertension. Circ J [Internet]. 2013 [cited 2018 Aug24];77(3):756–763. Available from: https://www.jstage.jst.go.jp/article/circj/77/3/77_CJ-12-1083/_article
Fine NM, Chen L, Bastiansen PM, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Cir Cardiovasc Imaging [Internet]. 2013 Sep 1;6(5):711–721. [cited 2018 Aug24]. Available from: http://circimaging.ahajournals.org/cgi/doi/10.1161/CIRCIMAGING.113.000640
Beghetti M, Schulze-Neick I, Berger RMF, et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol. 2016 Jan;15(203):325–330.
Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart [Internet]. 2016 May 1 [cited 2018 Aug26];102(Suppl 2): ii23–9. Available from: https://heart.bmj.com/content/102/Suppl_2/ii23
Zuckerman WA, Turner ME, Kerstein J, et al. Safety of cardiac catheterization at a center specializing in the care of patients with pulmonary arterial hypertension. Pulm Circ [Internet]. 2013 Dec [cited 2018 Aug26];3(4):831–839. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070826/
Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol [Internet]. 2006 Dec 19 [cited 2018 Aug26];48(12):2546–2552. Available from: http://www.sciencedirect.com/science/article/pii/S0735109706023382
Taylor CJ, Derrick G, McEwan A, et al. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth [Internet]. 2007 Apr [cited 2018 Aug26];98(5):657–661. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0007091217348523
Jing Z-C, Jiang X, Han Z-Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J [Internet]. 2009 Jun 1 [cited 2019 Jan20];33(6):1354–1360. Available from: https://erj.ersjournals.com/content/33/6/1354
Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001 Jan 30;103(4):544–548.
Douwes JM, Humpl T, Bonnet D, et al. Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP registry. J Am Coll Cardiol. 2016 Mar 22;67(11):1312–1323.
Mullen MP. Diagnostic strategies for acute presentation of pulmonary hypertension in children: particular focus on use of echocardiography, cardiac catheterization, magnetic resonance imaging, chest computed tomography, and lung biopsy. Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S23–26.
Lammers AE, Apitz C, Zartner P, et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart [Internet]. 2016 May [cited 2018 Sep8];102(Suppl 2):ii1–13. Available from: http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2015-307792
Latus H, Kuehne T, Beerbaum P, et al. Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart [Internet]. 2016 May [cited 2018 Sep8];102(Suppl 2):ii30–5. Available from: http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2015-308246
Moledina S, Pandya B, Bartsota M, et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Cir Cardiovasc Imaging [Internet]. 2013 May 1 [cited 2018 Sep8];6(3):407–414. Available from: http://circimaging.ahajournals.org/cgi/doi/10.1161/CIRCIMAGING.112.000082
Caro-Domínguez P, Compton G, Humpl T, et al. Pulmonary arterial hypertension in children: diagnosis using ratio of main pulmonary artery to ascending aorta diameter as determined by multi-detector computed tomography. Pediatr Radiol. 2016 Sep;46(10):1378–1383.
Berteloot L, Proisy M, Jais J-P, et al. Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease. Pediatr Radiol. 2019 Jan 16. doi: 10.1007/s00247-018-04331-y.
Lammers AE, Diller G-P, Odendaal D, et al. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Arch Dis Child. 2011 Feb;96(2):141–147.
Rausch CM, Taylor AL, Ross H, et al. Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. Int J Cardiol [Internet]. 2013 Nov 30 [cited 2018 Sep8];169(6):445–448. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909671/
Yetman AT, Taylor AL, Doran A, et al. Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. Am J Cardiol [Internet]. 2005 Mar 1 [cited 2018 Sep8];95(5):697–699. Available from: https://www.ajconline.org/article/S0002-9149(04)01806-5/abstract
Douwes JM, Hegeman AK, van der Krieke MB, et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. Int J Cardiol [Internet]. 2016 Jan 1 [cited 2019 Jan8];202:34–39. Available from: http://www.sciencedirect.com/science/article/pii/S0167527315303922
Ploegstra M-J, Zijlstra WMH, Douwes JM, et al. Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. Int J Cardiol. 2015 Apr 1;184:198–207.
Humpl T, Berger RMF, Austin ED, et al. Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry. Cardiol Young. 2017 Aug;27(6):1123–1132.
Weinstein AA, Chin LMK, Keyser RE, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med [Internet]. 2013 May [cited 2018 Aug27];107(5):778–784. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0954611113000553
Chan L, Chin LMK, Kennedy M, et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest [Internet]. 2013 Feb [cited 2018 Aug27];143(2):333–343. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0012369213600793
Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014 Jun;43(6):1691–1697.
Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs Internet]. 2011 Apr 1 [cited 2018 Sep9];20(4):567–576. Available from: https://doi.org/10.1517/13543784.2011.565048
Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012 Jan 17;125(2):324–334.
Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014 May 13;129(19):1914–1923.
Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med [Internet]. 2013 Mar 15 [cited 2018 Aug23];187(6):572–575. Available from: https://www.atsjournals.org/doi/abs/10.1164/rccm.201210-1928PP
Research C for DE and. Drug safety and availability - FDA drug safety communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [Internet]. [cited 2018 Aug30]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm317123.htm?source=govdelivery
Research C for DE and. drug safety and availability - FDA drug safety communication: FDA clarifies warning about pediatric use of revatio (sildenafil) for Pulmonary arterial hypertension [Internet]. [cited 2018 Aug30]. Available from: https://www.fda.gov/drugs/drugsafety/ucm390876.htm
Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol [Internet]. 2012 Jun [cited 2018 Aug30];33(5):683–688. Available from: http://link.springer.com/10.1007/s00246-012-0180-4
A study of tadalafil in pediatric participants with pulmonary arterial hypertension (PAH) - full text view - clinicaltrials.gov [Internet]. [cited 2018 Aug30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01824290
Ivy D. PULMONARY HYPERTENSION IN CHILDREN. Cardiol Clin [Internet]. 2016 Aug [cited 2018 Jun13];34(3):451–472. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959130/
Ghofrani H-A, Humbert M, Langleben D, et al. Riociguat: mode of action and clinical development in pulmonary hypertension. Chest [Internet]. 2017 Feb [cited 2018 Sep9];151(2):468–480. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0012369216491117
Spreemann T, Bertram H, Happel CM, et al. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Pulm Circ. 2018 Mar;8(1):2045893217743123.
Galiè N, Müller K, A-V S, et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015 May;45(5):1314–1322.
Trial detail - UK clinical trial gateway [Internet]. [cited 2018 Aug23]. Available from: https://ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialNumber=NCT02562235
Vignon-Zellweger N, Heiden S, Miyauchi T, et al. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci [Internet]. 2012 Oct [cited 2018 Aug31];91(13–14):490–500. Available from: http://linkinghub.elsevier.com/retrieve/pii/S002432051200149X
Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009 Dec;68(6):948–955.
Berger RMF, Haworth SG, Bonnet D, et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 1;202:52–58.
Berger RMF, Gehin M, Beghetti M, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3: FUTURE-3: investigating the dosing of bosentan in paediatric patients. Br J Clin Pharmacol [Internet]. 2017 Aug [cited 2018 Aug23];83(8):1734–1744. Available from:
European medicines agency - - tracleer [Internet]. [cited 2018 Aug31]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000401/human_med_001100.jsp
Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program. Pediatr Res. 2008 Aug;64(2):200–204.
Takatsuki S, Eb R, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013 Jan [cited 2018 Aug23];48(1):27–34. Internet Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412194/
Efficacy and safety of ambrisentan in children 8-18yrs - full text view - clinicaltrials.gov [Internet]. [cited 2018 Aug31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01332331
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J MedInternet. 2013 Aug 29 [cited 2018 Aug31];369(9):809–818. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1213917
A study to assess whether macitentan delays disease progression in children with pulmonary arterial hypertension (PAH) - full text view - clinicaltrials.gov [Internet]. [cited 2018 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02932410
Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med [Internet]. 1999 Jun 1 [cited 2018 Sep1];159(6):1925–1932. Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm.159.6.9804054
Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999 Mar 9;99(9):1197–1208.
Yung D. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation [Internet]. 2004 Jul 26 [cited 2018 Aug28];110(6):660–665. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000138104.83366.E9
Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007 Jun;93(6):739–743.
Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006 Dec;28(6):1195–1203.
Levy M, M-J DC, Nadaud S, et al. Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol. 2018 Aug;1(264):153–157.
Olschewski H, Naeije R, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329.
Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Jan 15;51(2):161–169.
Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag [Internet]. 2009 [cited 2018 Aug23];5:325–331. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672461/
Moreno‐Galdó A, Torrent‐Vernetta A, Messa I de M, et al. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol [Internet]. 2015 Apr 1 [cited 2018 Sep1];50(4):370–379. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.23044
Alehan D, Yıldırım I, Şahin M, et al. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. Cardiol Young [Internet]. 2012 Aug [cited 2018 Sep2];22(4):396–403. Available from: https://www.cambridge.org/core/journals/cardiology-in-the-young/article/longterm-inhaled-iloprost-use-in-children-with-pulmonary-arterial-hypertension/E36A7C5337F2F178F078E971DDE74A7E
Mulligan C, Beghetti M. Inhaled iloprost for the control of acute pulmonary hypertension in children: A systematic review. Pediatr Crit Care Med [Internet]. 2012 Jul [cited 2018 Aug23];13(4):472–480. Available from: https://insights.ovid.com/crossref?an=00130478-201207000-00016
Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med [Internet]. 2015 Dec 24 [cited 2018 Aug23];373(26):2522–2533.
Gallotti R, Drogalis-Kim DE, Satou G, et al. Single-center experience using selexipag in a pediatric population. Pediatr Cardiol. 2017 Oct;38(7):1405–1409.
Geerdink LM, Bertram H, Hansmann G. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulm Circ [Internet]. 2017 May 12 [cited 2018 Sep1];7(2):551–554. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467934/
A clinical study of to confirm the doses of selexipag in children with pulmonary arterial hypertension - full text view - clinicaltrials.gov [Internet]. [cited 2018 Sep3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03492177
Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med [Internet]. 2015 Aug 27 [cited 2018 Sep2];373(9):834–844. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1413687
Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47(6):1727–1736.
Zijlstra WMH, Douwes JM, Rosenzweig EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014 May 27;63(20):2159–2169.
Chiu JS, Zuckerman WA, Turner ME, et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. J Heart Lung Transplant [Internet]. 2015 Mar [cited 2018 Aug23];34(3):376–380. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1053249815000066
Baruteau A-E, Belli E, Boudjemline Y, et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg [Internet]. 2015 Mar 1 [cited 2018 Aug23];47(3):e105–10. Available from: https://academic.oup.com/ejcts/article/47/3/e105/523590
Sandoval J, Gomez-Arroyo J, Gaspar J, et al. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: beyond palliative treatments. J Cardiol [Internet]. 2015 Oct [cited 2018 Sep8];66(4):304–314. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0914508715000350
Sandoval J, Pulido T, Sandoval JP, et al. Balloon dilation atrial septostomy and potts anastomosis for severe pulmonary arterial hypertension: why, when, and how. Adv Pulm Hypertens [Internet]. 2016 Jan [cited 2018 Sep8];15(1):19–25. Available from: http://advancesinph.org/doi/10.21693/1933-088X.15.1.19
Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998 Aug;32(2):297–304.
Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart [Internet]. 2006 Jul [cited 2018 Sep8];92(7):969–972. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860701/
Sandoval J, Torbicki A. Atrial Septostomy. In: Voelkel NF, Schranz D, editorsThe right ventricle in health and disease. Internet]. New York, NY: Springer; 2015 [cited 2018 Sep8] p. 419–437. Respiratory Medicine.
Sandoval J, Gaspar J, Peña H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011 Dec;38(6):1343–1348.
Baruteau A-E, Serraf A, Lévy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg [Internet]. 2012 Sep [cited 2018 Aug23];94(3):817–824. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0003497512007837
Grady RM, Eghtesady P. Potts shunt and pediatric pulmonary hypertension: what we have learned. Ann Thorac Surg [Internet]. 2016 Apr [cited 2018 Sep2];101(4):1539–1543. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0003497515014290
Boudjemline Y, Sizarov A, Malekzadeh-Milani S, et al. Safety and feasibility of the transcatheter approach to create a reverse potts shunt in children with idiopathic pulmonary arterial hypertension. Can J Cardiol [Internet]. 2017 Sep 1 [cited 2019 Jan8];33(9):1188–1196. Available from: http://www.sciencedirect.com/science/article/pii/S0828282X17303100
George MP, Champion HC, Pilewski JM. Lung transplantation for pulmonary hypertension. Pulm Circ [Internet]. 2011 Apr [cited 2018 Sep9];1(2):182–191. Available from: http://journals.sagepub.com/doi/10.4103/2045-8932.83455
Kirkby S, Hayes D. Pediatric lung transplantation: indications and outcomes. J Thorac Dis [Internet]. 2014 Aug [cited 2018 Sep2];6(8):1024–1031. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133536/
Goldstein BS, Sweet SC, Mao J, et al. Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience. J Heart Lung Transplant [Internet]. 2011 Oct 1 [cited 2018 Sep9];30(10):1148–1152. Available from: https://www.jhltonline.org/article/S1053-2498(11)00946-6/abstract
Goldfarb SB, Levvey BJ, Cherikh WS, et al. Registry of the International society for heart and lung transplantation: twentieth pediatric lung and heart-lung transplantation Report—2017; focus theme: allograft ischemic time. J Heart Lung Transplant [Internet]. 2017 Oct [cited 2018 Sep2];36(10):1070–1079. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1053249817319083